Prostate Cancer Genetic Risk Evaluation and Screening Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age35-74
SponsorMassachusetts General Hospital

About this trial

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Eligibility criteria

Qualifiers

Men 35-74 years old

No known diagnosis of prostate cancer

Life expectancy >10 years

Meet cohort A, B, or C criteria

Disqualifiers

Prior diagnosis or treatment of prostate cancer

Inability to undergo prostate MRI

Inability to receive MRI contrast agent

Trial design

Treatments tested in this trial

  • Prostate cancer screening

Treatment groups

400 Participants
are divided into 3 treatment groups

Sponsors and collaborators